0000000000469806

AUTHOR

Giovani Triolo

0000-0002-7067-6896

showing 34 related works from this author

Cognitive deficits in Behçet disease

2000

cognitive BehçetSettore MED/26 - Neurologia
researchProduct

Alterations of the beneficial effect of deep inspiration in scleroderma: relationships between lung function and imaging.

2007

<i>Background:</i> It has been postulated that the beneficial effects of deep inspiration are dependent on the magnitude of airway distension by virtue of airway to parenchyma interdependence. <i>Objective:</i> This study was designed to examine whether the changes that occur in pulmonary fibrosis affect the beneficial effect of deep inspiration. <i>Methods:</i> Thirty-one subjects with scleroderma underwent lung volume and diffusion capacity assessment as well as high-resolution computed tomography. To assess the effect of deep inspiration, each subject underwent methacholine provocations in the absence of deep breaths. When the targeted change in lung f…

MalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyPulmonary FibrosisVital CapacityDistensionSettore MED/10 - Malattie Dell'Apparato RespiratorioBronchial Provocation TestsSclerodermaBronchoconstrictor AgentsScleroderma LocalizedForced Expiratory VolumeParenchymamedicineHumansLungMethacholine ChlorideBronchusLungbusiness.industryRespiratory diseaseInterstitial lung diseaseMiddle Agedrespiratory systemmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structureInhalationRespiratory Mechanicsconnettive diseases lung inflation imagingFemaleTomography X-Ray ComputedAirwaybusiness
researchProduct

Circulating immune complexes and platelet thromboxane synthesis in patients with insulin-dependent (type I) diabetes mellitus

1984

Platelets from diabetic subjects with circulating immune complexes (CIC) synthesized greater amounts of thromboxane than did platelets from CIC-negative patients or controls. In view of the known action of CIC on platelet function, a relationship between these two factors may be suggested in the initiation and progression of microangiopathy in diabetes.

Blood PlateletsMalemedicine.medical_specialtyThromboxaneInsulin AntibodiesEndocrinology Diabetes and MetabolismAntigen-Antibody ComplexPathogenesisImmune systemInternal medicineDiabetes mellitusmedicineInternal MedicineHumansPlateletIn patientChildbusiness.industryMicroangiopathyThromboxanesComplement C3medicine.diseaseImmune complexAntibodies Anti-IdiotypicThromboxane B2Diabetes Mellitus Type 1EndocrinologyImmunoglobulin GImmunologyFemalebusinessDiabetes
researchProduct

Are Toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes?

2011

In this paper we focus our attention on the role of two families of receptors, Toll-like receptors (TLR) and decoy receptors (DcR) involved in the generation of systemic lupus erythematosus (SLE) and lupus-like syndromes in human and mouse models. To date, these molecules were described in several autoimmune disorders such as rheumatoid arthritis, antiphospholipids syndrome, bowel inflammation, and SLE. Here, we summarize the findings of recent investigations on TLR and DcR and their role in the immunopathogenesis of the SLE.

lcsh:Immunologic diseases. AllergyChemokineImmunologyInflammationAutoimmunityReview ArticleCell Communicationmedicine.disease_causeAutoantigensAutoimmunityMiceimmune system diseasesToll-like receptormedicineImmunology and AllergyAnimalsHumansLupus Erythematosus SystemicDecoy receptorsReceptorskin and connective tissue diseasesSettore MED/04 - Patologia GeneraleToll-like receptors decoy receptors systemicic erythematous lupusSystemic lupus erythematosusbiologybusiness.industryToll-Like ReceptorsGeneral Medicinemedicine.diseaseImmunity Innatedecoy receptorDisease Models AnimalTumor Necrosis Factor Decoy ReceptorsRheumatoid arthritisImmunologybiology.proteinsystemicic erythematous lupusmedicine.symptomChemokinesbusinesslcsh:RC581-607Tumor Necrosis Factor Decoy ReceptorsSignal Transduction
researchProduct

Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects

2003

Fifty-six young central obese patients were investigated to evaluate relationships between soluble E-selectin (sE-S), angiotensin-converting enzyme (ACE) gene polymorphism, left ventricular function and structure, and carotid morphology by determination of sE-S and ACE genotypes. Our results indicated that central obese subjects with concomitant higher levels of sE-S and ACE DD genotype may be characterized by early cardiovascular alterations and then considered a particular subset of subjects at higher risk of cardiovascular disease.

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina Internaangiotensin-converting-enzyme cardiovascular damageGenotypeArteriosclerosisEndocrinology Diabetes and MetabolismBlood PressureDiseasecentral obese subjectsPeptidyl-Dipeptidase ABody Mass Indexcirculating E-selectin genotype; angiotensin-converting-enzyme cardiovascular damage; central obese subjectsEndocrinologyRisk FactorsInternal medicineGenotypeE-selectinmedicineHumansInsulinObesityAllelesbiologyVentricular functionHemodynamicsHeartAngiotensin-converting enzymeGlucose Tolerance TestSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheIsoenzymesCarotid ArteriesEndocrinologyCardiovascular DiseasesEchocardiographyConcomitantbiology.proteinRegression AnalysisFemaleObese subjectsGene polymorphismE-Selectincirculating E-selectin genotypeMetabolism
researchProduct

Serum levels of type III procollagen peptide in diabetes mellitus.

1989

Serum levels of type III procollagen peptide (P-III-P) were investigated in 19 patients with type 1 (insulin-dependent) and in 48 (25 orally treated, 23 insulinized) patients with type 2 (non insulin-dependent) diabetes mellitus. Among patients with type 2 diabetes, 16 orally treated and 14 insulin-treated subjects had macrovascular complications. P-III-P levels were not correlated with the duration of diabetes and with glucose control, nor were there any significant sex and age differences in the levels. P-III-P values were significantly higher in the sera of insulin-treated non insulin-dependent diabetic patients with macroangiopathy. These high values (18.5 +/- 10.8 ng/ml) were in contra…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryType 2 diabetesBiochemistryPathogenesisEndocrinologyInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansSensitizationPancreatic hormoneAgedbusiness.industryInsulinBiochemistry (medical)RadioimmunoassayGeneral MedicineMiddle Agedmedicine.diseaseProcollagen peptidasemedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 1Diabetes Mellitus Type 2FemalebusinessProcollagenHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
researchProduct

Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies

2015

In recent years, mesenchymal stromal cells (MSCs) have been largely investigated and tested as a new therapeutic tool for several clinical applications, including the treatment of different rheumatic diseases. MSCs are responsible for the normal turnover and maintenance of adult mesenchymal tissues as the result of their multipotent differentiation abilities and their secretion of a variety of cytokines and growth factors. Although initially derived from bone marrow, MSCs are present in many different tissues such as many peri-articular tissues. MSCs may exert immune-modulatory properties, modulating different immune cells in both in vitro and in vivo models, and they are considered immune-…

AdultCancer ResearchpathogenesiCellular differentiationImmunologyCell- and Tissue-Based TherapyBone Marrow CellsMesenchymal Stem Cell TransplantationRegenerative MedicineRegenerative medicineAutoimmune DiseaseAutoimmune DiseasesChondrocytesImmune systemIn vivoBone MarrowRheumatic DiseasesmedicineHumansImmunology and Allergyrheumatic diseaseGenetics (clinical)TransplantationOsteoblastsMesenchymal Stromal Cellbusiness.industryOsteoblastMesenchymal stem cellMesenchymal Stem CellsCell DifferentiationCell BiologyChondrocyteClinical trialmedicine.anatomical_structureregenerative therapyOncologymesenchymal stromal cells; pathogenesis; regenerative therapy; rheumatic disease; Adult; Autoimmune Diseases; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell- and Tissue-Based Therapy; Chondrocytes; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stromal Cells; Osteoblasts; Regenerative Medicine; Rheumatic DiseasesImmunologyBone Marrow CellBone marrowStem cellbusinessHuman
researchProduct

Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome.

2012

OBJECTIVES: In chronic inflammatory disorders, interleukin (IL)-22 may act either as a protective or as a pro-inflammatory cytokine. At mucosal sites, IL-22 is mainly produced by CD4(+) T cells and by a subset of mucosal natural killer (NK) cells expressing the receptor NKp44 (NKp44(+) NK cells). The aim of this study was to investigate the IL-22 expression in the salivary glands of patients with primary Sjögren's syndrome (pSS). METHODS: Minor salivary gland biopsies were obtained from 19 patients with pSS and 16 with non-specific chronic sialoadenitis. Quantitative gene expression analysis by TaqMan real-time PCR and immunohistochemistry for IL-17, IL-22, IL-23 and STAT3 (signal transduce…

AdultCD4-Positive T-LymphocytesMaleSTAT3 Transcription FactorAnkylosing Spondylitis IL-22 NKp44NK cells intestinal inflammationmedicine.medical_treatmentImmunologySalivary Glands MinorInterleukin-23General Biochemistry Genetics and Molecular BiologySialadenitisInterleukin 22PathogenesisRheumatologyintestinal inflammationIL-22Immunology and AllergyMedicineHumansRNA MessengerSTAT3ReceptorAgedAnkylosing SpondylitibiologySalivary glandNatural Cytotoxicity Triggering Receptor 2business.industryReverse Transcriptase Polymerase Chain ReactionInterleukinsInterleukin-17InterleukinMiddle AgedNKp44NK cellKiller Cells NaturalSettore MED/16 - ReumatologiaCytokinemedicine.anatomical_structureSjogren's SyndromeCase-Control StudiesImmunologybiology.proteinImmunohistochemistryFemalebusinessAnnals of the rheumatic diseases
researchProduct

New approaches in the treatment of Adamantiades-Behçet's disease.

2005

Purpose of review To update clinicians on the recent advances in the treatment of Adamantiades-Behcet's disease. Recent findings Interferon-α-2a and infliximab have proved able to induce prompt remission in the vast majority of Adamantiades-Behcet's patients with DMARD-resistant uveoretinitis. Efficacy of interferon-α-2a has also been reported for mucocutaneous lesions, arthritis, and (more anecdotally) for neuro-Behcet, while results from small case series suggest that infliximab is beneficial for mucocutaneous lesions and (more anecdotally) for arthritis and gastro-intestinal manifestations. Two cases of neuro-Behcet treated with infliximab showed a complete resolution. Finally, in a rand…

medicine.medical_specialtyMucocutaneous zoneArthritisBehcet's diseaseDiseaseInterferon alpha-2Receptors Tumor Necrosis Factorlaw.inventionEtanerceptEtanerceptRheumatologyRandomized controlled triallawAntibodies Monoclonal; Behcet Syndrome; Chaperonin 60; Humans; Immunoglobulin G; Immunologic Factors; Interferon-alpha; Receptors Tumor Necrosis Factor; Recombinant ProteinsmedicineHumansImmunologic FactorsIFN-α2abusiness.industryBehcet SyndromeAntibodies MonoclonalInterferon-alphaChaperonin 60medicine.diseaseDermatologyeye diseasesInfliximabAdamantiades-Behçet's diseaseInfliximabRecombinant Proteinsstomatognathic diseasesImmunoglobulin GImmunologyTumour necrosis factorbusinessTolerizationUveitismedicine.drugCurrent opinion in rheumatology
researchProduct

Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation an…

2010

Introduction: Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α) that has been introduced recently for Behcet's disease (BD) patients who were resistant to standard treatment. The aim of this study was to analyse the functional changes of Vγ9/Vδ2 T lymphocytes in both active and inactive disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity. Methods: We investigated 1) cell expansion, 2) expression of TNFRII receptor, 3) perforin and gamma interferon (IFN) content, 4) release of granzyme A (GrA) and 5) phenotype changes, in vitro and in vivo, in Vγ9/Vδ2 T lymphocytes by means of fluorescence-activated cell sorter …

AdultAdolescentCell SurvivalT cellLymphocyteT-LymphocytesImmunologyGranzymesInterferon-gammaYoung AdultRheumatologyAntigenmedicineImmunology and AllergyHumansReceptors Tumor Necrosis Factor Type IIInterferon gammaCells CulturedAgedCell ProliferationbiologyPerforinBehcet SyndromeAntibodies MonoclonalReceptors Antigen T-Cell gamma-deltaMiddle AgedInfliximabmedicine.anatomical_structurePhenotypeGranzymePerforinAntirheumatic AgentsCase-Control StudiesImmunologybiology.proteinGranzyme ATumor necrosis factor alphaFemalemedicine.drugResearch ArticleArthritis Research & Therapy
researchProduct

IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis.

2013

OBJECTIVE: To study the expression of interleukin (IL)-33 and to evaluate its relationship with macrophage polarisation in artery biopsy specimens from patients with giant cell arteritis (GCA). METHODS: IL-33, ST2, p-STAT-6 and perivascular IL-1 receptor-associated kinase 1 (p-IRAK1) tissue distribution was evaluated by immunohistochemistry. Inducible nitric oxide synthase and CD163 were also used by immunohistochemistry to evaluate the M1 and M2 polarisation, respectively. Quantitative gene expression analysis of IL-33, T-helper (Th)2-related transcription factor STAT6, Th2 cytokines (IL-4, IL-5, IL-25) and interferon (IFN)-γ was performed in artery biopsy samples obtained from 20 patients…

MalePathologymedicine.medical_specialtyImmunologyGiant Cell ArteritisInflammationGeneral Biochemistry Genetics and Molecular BiologyGiant cell arteritis IL-33 macrophagesRheumatologyGiant cell arteritiImmunology and AllergyMedicineHumansReceptorSTAT6AgedAged 80 and overInflammationAged; Aged 80 and over; Female; Giant Cell Arteritis; Humans; Immunohistochemistry; Inflammation; Interleukins; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; Temporal Arteries; Transcriptomebusiness.industryReverse Transcriptase Polymerase Chain ReactionInterleukinsInterleukinMiddle Agedmedicine.diseaseInterleukin-33ImmunohistochemistryTemporal ArteriesmacrophagesInterleukin 33Giant cell arteritisIL-33ImmunohistochemistryFemalemedicine.symptombusinessTranscriptomeCD163
researchProduct

Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet's disease: moderate correlation with anti-endothelial …

1999

We studied the in vitro E-selection expression of endothelial cells treated with sera from patients with Behcet's disease (BD) and factors (anti-endothelial cell antibodies, anti-neutrophil cytoplasmic antibodies, cytokines, and myeloperoxidase (MPO) that may contribute to adhesion molecule expression. A total of 21 patients with BD and 27 healthy controls were studied. In vitro E-selectin endothelial cell expression was investigated by ELISA after HUVEC incubation with sera or purified IgG from patients with BD and controls. Increased E-selectin expression was observed when endothelial cells were incubated with sera from patients with active disease or from patients with circulating anti-e…

AdultMaleNeutrophilsImmunologyCellIn Vitro TechniquesImmunoglobulin GAntibodies Antineutrophil CytoplasmicE-selectinmedicineImmunology and AllergyHumansCells CulturedAgedAutoantibodiesPeroxidasebiologyCell adhesion moleculeBehcet SyndromeAutoantibodyMiddle AgedMolecular biologyEndothelial stem cellmedicine.anatomical_structureMyeloperoxidaseImmunoglobulin GImmunologybiology.proteinCytokinesFemaleEndothelium VascularAntibodyE-SelectinClinical immunology (Orlando, Fla.)
researchProduct

Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.

2014

OBJECTIVE: The aim of this study was to evaluate the role of rituximab (RTX) in modulating the expression of the IL-17/IL-23 pathway in the salivary glands (SGs) of patients with primary SS (pSS). METHODS: Consecutive SG biopsies were obtained from 15 patients with pSS before and after 1 year of RTX therapy. The SG expression of IL-17, IL-23p19 and p-STAT3 was evaluated by immunohistochemistry at baseline and after RTX therapy. The role of mast cells in pSS patients in modulating the Th17 response and the immunologic effect of RTX on mast cells were also studied in in vitro experiments. RESULTS: IL-17 was overexpressed in the SGs of patients with pSS mainly by infiltrating T cells and mast …

AdultMaleSTAT3 Transcription FactorSjogren SyndromeApoptosisIn Vitro TechniquesInterleukin-23Peripheral blood mononuclear cellSalivary GlandsAntibodies Monoclonal Murine-DerivedRheumatologystomatognathic systemSettore BIO/13 - Biologia ApplicataBiopsyHumansMedicinePharmacology (medical)Mast CellsAgedmedicine.diagnostic_testbusiness.industryInterleukinsInterleukin-17IL17Middle AgedMast cellIn vitroSettore MED/16 - ReumatologiaSjogren's SyndromeTreatment Outcomemedicine.anatomical_structureApoptosisAntirheumatic AgentsImmunologyTh17 CellsImmunohistochemistryFemaleRituximabInterferonsInterleukin 17businessRituximabSignal Transductionmedicine.drug
researchProduct

Rapida induzione di remissione di un caso di malattia di Vogt-Koyonagi-Harada recidivante dopo terapia con infliximab

2006

Vogt-koyonagi-Harada
researchProduct

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

2010

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. ©…

MaleAntibodieReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptRandomized controlled triallawimmune system diseasesOutcome Assessment Health CareMonoclonalImmunology and Allergyskin and connective tissue diseasesAntirheumatic AgentAntibodies MonoclonalAntirheumatic AgentsTreatment OutcomeAntirheumatic AgentsFemalemedicine.drugHumanReceptormusculoskeletal diseasesAdultAnkylosingmedicine.medical_specialtyImmunologyDrug Administration ScheduleOutcome Assessment (Health Care)RheumatologyInternal medicinemedicineHumansSpondylitis AnkylosingSpondylitisSpondylitiAnkylosing spondylitisbusiness.industryTumor Necrosis Factor-alphaAnkylosing spondylitis; Etanercept; Infliximab; Adult; Antibodies Monoclonal; Antirheumatic Agents; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Male; Outcome Assessment (Health Care); Receptors Tumor Necrosis Factor; Spondylitis Ankylosing; Treatment Outcome; Tumor Necrosis Factor-alpha; Rheumatology; Immunology; Immunology and Allergymedicine.diseaseInfliximabRheumatologyInfliximabClinical trialAnkylosing spondylitistomatognathic diseasesImmunoglobulin GPhysical therapybusinessTumor Necrosis Factor
researchProduct

NF-κB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins

2005

Objective To determine whether prolongation of the inflammatory reaction in patients with Behcet's disease (BD) is related to apoptosis resistance and is associated with the up-regulation of antiapoptotic factors. Methods The percentage of cell death was evaluated by flow cytometry in peripheral blood mononuclear cells from 35 patients with BD and 30 healthy volunteers. The expression levels of antiapoptotic factors and NF-κB regulatory proteins were measured using Western blotting and immunohistochemical analyses. To down-regulate NF-κB nuclear translocation, BD T lymphocytes were exposed in vitro to thalidomide and subjected to transfection with NF-κB small interfering RNA. Results Althou…

AdultMaleSmall interfering RNAProgrammed cell deathT-LymphocytesT cellImmunologyCASP8 and FADD-Like Apoptosis Regulating Proteinbcl-X ProteinApoptosisCaspase 3TransfectionCaspase 8RheumatologyHumansImmunology and AllergyMedicinePharmacology (medical)fas ReceptorRNA Small InterferingCells CulturedDose-Response Relationship Drugbusiness.industryBehcet SyndromeIntracellular Signaling Peptides and ProteinsNF-kappa BTransfectionFlow CytometryFas receptorThalidomideUp-Regulationmedicine.anatomical_structureGene Expression RegulationProto-Oncogene Proteins c-bcl-2ApoptosisImmunologyLeukocytes MononuclearCancer researchFemalebusinessArthritis & Rheumatism
researchProduct

Behçet's disease and coeliac disease

1995

Celiac Diseasemedicine.medical_specialtybusiness.industryBehcet SyndromemedicineHumansGeneral MedicineBehcet's diseasemedicine.diseasebusinessDermatologyAntibodiesCoeliac diseaseThe Lancet
researchProduct

Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS

2013

Bariatric surgery represents a common approach for the control of severe morbid obesity, reducing caloric intake by modifying the anatomy of the gastrointestinal tract. Following jejunoileal bypass, a large spectrum of complications has been described, with rheumatic manifestation present in up to 20% of cases. Although bowel bypass syndrome, also called blind loop syndrome, is a well-recognized complication of jejunoileal bypass, the same syndrome was recognized in patients who had not had intestinal bypass surgery, and the term the 'bowel-associated dermatosis-arthritis syndrome' (BADAS) was coined. The pathogenesis of BADAS is as yet poorly understood and only few data concerning this is…

Short Bowel Syndromemedicine.medical_specialtyPediatricsmedicine.medical_treatmentJejunoileal bypass immune-related conditionsImmunologyJejunoileal bypassSkin DiseasesGastroenterologyImmune systemBlind loop syndromeJejunoileal BypassInternal medicinemedicineHumansImmunology and AllergyIn patientIntestinal bypassbusiness.industryBowel-associated dermatosis–arthritis syndromeArthritismedicine.diseaseCaloric intakeimmune-related conditionsBlind Loop SyndromeComplicationbusinessJejunoileal bypa
researchProduct

Inhibition of Fcγ Receptors in the Plasma of Subjects with Down's Syndrome

1993

Abstract Subjects with Down's syndrome have several immunological abnormalities. We examined the sera of 29 subjects with Down's syndrome for the presence of Fcγ receptor blocking and for the presence of anti-ssDNA antibodies by EA rosette inhibition. Fifty-five percent of Down subjects had levels of inhibition above the upper limit of normality in comparison to 7% of normal controls. The finding that after polyethylene glycol precipitation of selected sera giving high levels of EA rosette inhibition there was a reduction or a disappearance of the EA rosette inhibition could indicate that the blocking factors detected behaved as immune complexes. Since almost all subjects with anti-ssDNA an…

AdultDown syndromeErythrocytesRosette FormationAdolescentImmunologyDNA Single-StrandedAntigen-Antibody ComplexAntibodiesPolyethylene GlycolsPathology and Forensic MedicinePathogenesisImmune systemmedicineAnimalsChemical PrecipitationHumansImmunology and AllergyLymphocytesChildReceptorbiologyRosette (schizont appearance)Receptors IgGAutoantibodyInfantmedicine.diseaseImmunoglobulin AImmunoglobulin MChild PreschoolImmunoglobulin GImmunologybiology.proteinDown SyndromeAntibodyTrisomyChickensClinical Immunology and Immunopathology
researchProduct

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register

2014

Abstract Introduction Rituximab (RTX) is a monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) in association with methotrexate (MTX). Objectives To evaluate the efficacy and safety of RTX–MTX combination therapy compared with RTX alone in the treatment of RA. Methods We analyzed data from a prospective cohort study, the Italian biologic register GISEA, to investigate the efficacy and safety of rituximab. Moreover, the adverse events (AE) and the causes of discontinuation therapy were analyzed. Results We identified 338 RA patients, 162 treated with RTX and 176 with RTX–MTX. After 52 and 104 weeks of therapy the disease activity score in 28 joints and the H…

RegistrieMaleanti-CD20 rituximab; rheumatoid arthritis; GISEArheumatoid arthritisSettore MED/16 - REUMATOLOGIAAnti-CD20Arthritis RheumatoidAntibodies Monoclonal Murine-DerivedRheumatoidMonoclonalRegistriesProspective cohort studyGISEAAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome; RegistriesAntirheumatic AgentAntibodies MonoclonalMiddle AgedTreatment OutcomeRituximab rheumatoid arthritisAntirheumatic AgentsRheumatoid arthritisCombinationMonoclonalDrug Therapy CombinationFemaleRituximabRituximabHumanmedicine.drugmusculoskeletal diseasesAdultMurine-Derivedmedicine.medical_specialtyCombination therapyAntibodiesNOAnti-CD20; Methotrexate; Rheumatoid arthritis; RituximabDrug TherapyRheumatologyanti-CD20 rituximabInternal medicinemedicineHumansRheumatoid arthritisAdverse effectRheumatoid arthritiAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Registries; RheumatologyAgedbusiness.industryArthritismedicine.diseaseSurgeryDiscontinuationMethotrexateMethotrexatebusinessJoint Bone Spine
researchProduct

Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis

2015

Objective Ankylosing spondylitis (AS) is a common, highly heritable immune-mediated arthropathy that occurs in genetically susceptible individuals exposed to an unknown but likely ubiquitous environmental trigger. There is a close relationship between the gut and spondyloarthritis, as exemplified in patients with reactive arthritis, in whom a typically self-limiting arthropathy follows either a gastrointestinal or urogenital infection. Microbial involvement in AS has been suggested; however, no definitive link has been established. The aim of this study was to determine whether the gut in patients with AS carries a distinct microbial signature compared with that in the gut of healthy contro…

RikenellaceaebiologyImmunologyLachnospiraceaePorphyromonadaceaeIleumPrevotellaceaebiology.organism_classificationmedicine.diseasemedicine.anatomical_structureRheumatologyImmunologymedicineImmunology and AllergyReactive arthritisDysbiosisBacteroidaceaeArthritis & Rheumatology
researchProduct

Evidence that autophagy, but not the unfolded protein response, regulates the expression of IL-23 in the gut of patients with ankylosing spondylitis …

2013

OBJECTIVES: Interleukin (IL)-23 has been implicated in the pathogenesis of ankylosing spondylitis (AS). The aim of the study was to clarify the mechanisms underlying the increased IL-23 expression in the gut of AS patients. METHODS: Consecutive gut biopsies from 30 HLA-B27(+) AS patients, 15 Crohn's disease (CD) patients and 10 normal subjects were obtained. Evidence for HLA-B27 misfolding was studied. Unfolded protein response (UPR) and autophagy were assessed by RT-PCR and immunohistochemistry. The contribution of UPR and autophagy in the regulation of IL-23 expression was evaluated in in vitro experiments on isolated lamina propria mononuclear cells (LPMCs). RESULTS: Intracellular coloca…

AdultMaleProtein FoldingBiopsyImmunologyATG5Gene ExpressionInflammationdigestive systemArticleGeneral Biochemistry Genetics and Molecular BiologyATG12Young AdultCrohn DiseaseRheumatologyDownregulation and upregulationSettore BIO/13 - Biologia Applicataankylosing spondylitisAutophagymedicineInterleukin 23HumansImmunology and AllergySpondylitis AnkylosingHLA-B27 AntigenAgedMucous Membranebusiness.industryAutophagyInterleukinIleitisMiddle AgedIntestinesInterleukin 23Settore MED/16 - ReumatologiaImmunologyInterleukin-23 Subunit p19Unfolded Protein ResponseUnfolded protein responseFemalemedicine.symptombusinessAnnals of the Rheumatic Diseases
researchProduct

Phosphatidylserine counteracts physiological and pharmacological suppression of humoral immune response

1990

Phosphatidylserine (PS) is a necessary cofactor for protein kinase C (PKC) activation, and changes in the synthesis of PS have been shown to participate in the mechanism(s) involved in the transmembrane signaling of interleukin 1 (IL-1). In view of the age-associated defects in T-cell functions, in the present study we have addressed the question of whether an in vivo treatment with PS might interfere with such processes. Furthermore, the effect of an in vitro treatment with PS in human peripheral blood monocytes (PBMC) or splenocytes activated with a lectin mitogen, on the expression of IL-2 receptor, was assessed. While the process of ageing was accompanied by a marked decline of humoral …

Agingmedicine.medical_specialtyReceptor expressionPhosphatidylserinesIn Vitro Techniqueschemistry.chemical_compoundImmune systemInternal medicineImmune TolerancemedicineAnimalsHumansReceptorProtein Kinase CProtein kinase CPharmacologybiologyInterleukinRats Inbred StrainsReceptors Interleukin-2PhosphatidylserineRatsEndocrinologychemistryHumoral immunityLeukocytes Mononuclearbiology.proteinFemaleAntibodySpleenImmunopharmacology
researchProduct

Expansion of intestinal CD4+CD25highTreg cells in patients with ankylosing spondylitis: A putative role for interleukin-10 in preventing intestinal T…

2010

Objective Subclinical gut inflammation has been demonstrated in patients with ankylosing spondylitis (AS). This study was undertaken to determine the frequency of regulatory CD4+CD25high T cells (Treg cells) and to evaluate Treg cell–related cytokines (interleukin-2 [IL-2], transforming growth factor β [TGFβ], and IL-10) and transcription factors (FoxP3 and STAT-5) in the ileum of patients with AS. Methods Quantitative gene expression analysis, by reverse transcriptase–polymerase chain reaction, of Treg-related cytokines (IL-2, TGFβ, and IL-10) and transcription factors (STAT-5 and FoxP3) was performed on ileal biopsy specimens from 18 patients with AS, 15 patients with active Crohn's disea…

Interleukin 2medicine.diagnostic_testImmunologyFOXP3InflammationBiologyInterleukin 10RheumatologyIntestinal mucosaImmunologyBiopsymedicineInterleukin 23Immunology and AllergyPharmacology (medical)medicine.symptomTransforming growth factormedicine.drugArthritis & Rheumatism
researchProduct

Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss…

2003

Objective To compare the 2 most efficacious therapeutic regimens, intravenous immunoglobulin (IVIG) and anticoagulation with low molecular weight (LMW) heparin plus low-dose aspirin, in women with recurrent pregnancy loss associated with antiphospholipid antibodies (aPL). Methods We examined 40 women with recurrent abortion (at least 3 occurrences) and repeatedly positive test results for anticardiolipin or lupus anticoagulant. The subjects were randomly assigned to treatment with IVIG or LMW heparin plus low-dose aspirin. Both therapies were started when the women were pregnant as documented by a positive urine test. IVIG was stopped at the thirty-first week of gestation, aspirin at the th…

Adultmedicine.medical_specialtyAbortion HabitualAdolescentmedicine.drug_classImmunologyLow molecular weight heparinGastroenterologyRoute of administrationRandom AllocationRheumatologyAntiphospholipid syndromePregnancyInternal medicinemedicineImmunology and AllergyHumansPharmacology (medical)PregnancyLupus anticoagulantAspirinAspirinbusiness.industryAnticoagulantPregnancy OutcomeAnticoagulantsImmunoglobulins IntravenousHeparinHeparin Low-Molecular-Weightmedicine.diseaseAntiphospholipid SyndromeSurgeryPregnancy ComplicationsTreatment OutcomeDrug Therapy CombinationFemalebusinessmedicine.drugArthritis and rheumatism
researchProduct

Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity.

2014

OBJECTIVE: The aim of this study was to assess the expression of IL-22, IL-22 receptor 1 (IL-22R1), IL-22 binding protein (IL-22BP) and p-STAT3 in muscle tissue from patients with PM and DM. METHODS: Levels of IL-22, IL-22R1, IL-22BP and STAT3 mRNA were quantified by RT-PCR. The expression of IL-22, IL-22R1, IL-22BP and p-STAT3 was also analysed using immunohistochemistry. RESULTS: Significant modulation of the IL-22 pathway was observed in inflammatory myopathic tissues. In particular, a significant overexpression of IL-22 at the protein but not the mRNA level was observed in PM/DM tissues and was correlated with myositis activity. IL-22R1 aberrant expression was also observed among infilt…

Muscle tissueSTAT3 Transcription FactorPathologymedicine.medical_specialtyBiopsyPolymyositisSeverity of Illness IndexDermatomyositisInterleukin 22NecrosisRheumatologySettore BIO/13 - Biologia ApplicataMedicineMyocyteHumansPharmacology (medical)RNA MessengerReceptorMuscle SkeletalPolymyositiInflammationbusiness.industrySettore MED/27 - NeurochirurgiaInterleukinsReceptors InterleukinDermatomyositismedicine.diseasePolymyositisSettore MED/16 - Reumatologiamedicine.anatomical_structureInterleukin 22Case-Control StudiesImmunohistochemistryInterleukin 17businessSignal Transduction
researchProduct

Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: a genetically determined defect of C4 influences immunological parameter…

2003

Abstract Subjects with certain HLA alleles have a higher risk of specific autoimmune diseases than those without these alleles. The 8.1 ancestral haplotype (AH) is a common Caucasoid haplotype carried by most people who type for HLA-B8,DR3. It is unique in its association with a wide range of immunopathological diseases. To gain insight into the identification of the mechanism(s) of disease susceptibility of 8.1 AH carriers, we have investigated the prevalence of circulating immune complexes and non-organ-specific autoantibodies in healthy carriers of the haplotype. The results show that carriers of 8.1 AH display both a significant increased prevalence of immune complexes and higher titers…

AdultMaleEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenBiologyAutoimmune DiseasesHLA-B8 AntigenImmune systemHLA-DR3 AntigenAntigenGene FrequencyHLA AntigensGenetic predispositionmedicineHumansAlleleAllelesPharmacologyAutoimmune diseaseGeneticsHaplotypeAutoantibodyComplement C4General MedicineMiddle Agedmedicine.diseaseHaplotypesImmunologyFemaleBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

Is minor salivary gland biopsy more than a diagnostic tool in primary Sjorgren's syndrome? Association between clinical, histopathological, and molec…

2014

Objectives: Several histological scoring systems, including the focus score, performed in minor salivary glands (MSGs) by hematoxylin-eosin (H&E) staining, have been employed in clinical practice to assess the inflammatory infiltrate and provide the diagnosis of primary Sjorgren's syndrome (pSS). Aims of this study were to integrate different scoring systems and identify potential differences in the molecular profile of lymphoid cytokines related to germinal center (GC) formation and clinical subsets in pSS. Methods: Overall, 104 pSS patients and 40 subjects with sicca non-pSS were retrospectively evaluated. MSG biopsies were evaluated by H&E and immunofluorescence to assess histological pa…

MalePathologyT-LymphocytesBiopsyRetrospective Studiesalivary glands biopsyB-Lymphocytesmedicine.diagnostic_testbiologyLTαLTβMedicine (all)HypergammaglobulinemiaB-LymphocyteCXCL13CXCL12Middle AgedSjogren's syndrome salivary glands biopsySjogren's SyndromeCytokinesBAFFFemaleAntibodyHumanmusculoskeletal diseasesAdultmedicine.medical_specialtyBAFF; CCL19; CCL21; CCR7; CXCL12; CXCL13; CXCR4; CXCR5; Germinal center; LTα; LTβ; Minor salivary glands; Sjorgren's syndrome; Adult; B-Lymphocytes; Biomarkers; Biopsy; Cytokines; Female; Germinal Center; Humans; Male; Middle Aged; Retrospective Studies; Salivary Glands Minor; Sjogren's Syndrome; T-Lymphocytes; Rheumatology; Anesthesiology and Pain Medicine; Medicine (all)ImmunofluorescenceSalivary Glands MinorSalivary Glandstomatognathic systemRheumatologyInternal medicineBiopsyCCL19medicineHumansCXCL13B-cell activating factorCytokineRetrospective StudiesCXCR4Minor salivary glandbusiness.industryRetrospective cohort studyGerminal centerBiomarkermedicine.diseaseeye diseasesRheumatologyCXCR5Minorstomatognathic diseasesAnesthesiology and Pain MedicineT-LymphocyteSjorgren's syndromebiology.proteinbusinessBiomarkersCCL21CCR7
researchProduct

Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima–media thickness in female patients with active rheumatoid ar…

2009

The objective of the study is to evaluate the effect of TNF inhibition on carotid thickness over a 2-year period. 144 women with RA diagnosed according to ACR criteria, without clinical evidence of cardiac and/or vascular disease were enrolled and compared with 78 matched controls. All patients received methotrexate (15–20 mg weekly) for 3 months. Responders (n = 79) continued to be treated with methotrexate, non-responders (n = 40) moved to methotrexate plus a TNF alpha antagonist. Echosonographic studies of carotids were obtained before and after 2-year follow-up. A significant decrease of ca-IMT was observed in anti-TNF-treated patients (P < 0.001); on the other hand, no significant vari…

AdultCarotid Artery Diseasesmedicine.medical_specialtyImmunologyTNFGastroenterologyArthritis RheumatoidRheumatologyInternal medicineRheumatoid arthritis TNF DMARDs AtherosclerosisFemale patientmedicineHumansImmunology and AllergyRheumatoid arthritiUltrasonographyTumor Necrosis Factor-alphaVascular diseasebusiness.industryAntagonistMiddle AgedAtherosclerosismedicine.diseaseRheumatologySurgerySettore MED/16 - ReumatologiaDMARDMethotrexateTreatment OutcomeIntima-media thicknessAntirheumatic AgentsRheumatoid arthritiscardiovascular systemDrug Therapy CombinationFemaleMethotrexateTumor necrosis factor alphaTunica IntimaTunica Mediabusinessmedicine.drugRheumatology International
researchProduct

Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome

2012

We have recently demonstrated that interleukin (IL)-22, mainly produced by T-helper 17 effector cells, natural killer (NK)p44+NK cells and epithelial cells, may be potentially involved in the pathogenesis of primary Sjogren's syndrome (pSS).1 The IL-22/IL-22R pathway is known to play a role in the emergence of T and B-cell lymphoma2 ,3 and pSS is considered a risk factor for the development of lymphoma.4 Rituximab, which has historically been used for the treatment of B-cell lymphoma,5 has also been considered to be effective in the therapy of pSS.6 Ten consecutive patients with pSS (eight women and two men, with a mean duration of disease of 48±18 months), diagnosed according to the Americ…

biologybusiness.industryImmunologyInterleukinmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyLymphomaInterleukin 22Pathogenesissjogren's syndromestomatognathic diseasesRituximab sjogren's syndromeRheumatologyMonoclonalImmunologymedicinebiology.proteinImmunology and AllergyRituximabAntibodyRisk factorbusinessRituximabmedicine.drug
researchProduct

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.

2013

Introduction Primary Sjögren’s syndrome (pSS) is an autoimmune disorder affecting exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular involvement leading to a worsening of disease prognosis. Current therapeutic options are mainly empiric and often translated by other autoimmune diseases. In the last few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS. Patients with early active disease appear to be those who could benefit the most from RTX. The aim of this study was to investigate the efficacy and safety of RTX in comparison to disease modifying anti-rheumatic drugs (DMARDs) in early active pSS patients. …

AdultMaleReceptors CXCR5musculoskeletal diseasesReceptors CXCR4Salivamedicine.medical_specialtySjogren's syndrome RituximabTime FactorsBiopsyImmunologyGene ExpressionDiseaseSalivary GlandsAntibodies Monoclonal Murine-Derivedstomatognathic systemRheumatologyInternal medicineBiopsyHumansImmunology and AllergyMedicineProspective StudiesProspective cohort studyAdverse effectFatiguePain Measurementmedicine.diagnostic_testSalivary glandReverse Transcriptase Polymerase Chain Reactionbusiness.industryMiddle AgedChemokine CXCL13Chemokine CXCL12Rheumatologystomatognathic diseasesTreatment Outcomemedicine.anatomical_structureSjogren's syndromeAntirheumatic AgentsImmunologyFemaleRituximabSelf ReportRituximabbusinessFollow-Up StudiesResearch Articlemedicine.drug
researchProduct

Nerve conduction velocity and circulating immunocomplexes in type 1 diabetic children.

1991

There is evidence from several laboratories of an increased prevalence of circulating immuno-complexes (CIC) in diabetic patients. It has also been suggested that CIC are pathogenetically related to chronic diabetic complications. The aim of this study was to assess peripheral nerve function in children with Type 1 diabetes and to evaluate the relationship between the neurophysiological abnormalities and the possible presence of CIC. The investigation was carried out in 25 Type 1 diabetic patients ranging in age from 7-19 years and in 20 normal controls. Neurophysiological assessment was performed to evaluate motor and sensory conduction velocity on median and tibial nerves. IgG-CIC were de…

Malemedicine.medical_specialtyDiabetic neuropathyAdolescentSensory Receptor CellsNeural ConductionSensory systemAntigen-Antibody ComplexGastroenterologyNerve conduction velocityPathogenesisDiabetic NeuropathiesInternal medicineElectroneuronographymedicineReaction TimeHumansPeripheral NervesChildMotor NeuronsType 1 diabetesbusiness.industryGeneral Medicinemedicine.diseaseEndocrinologyDiabetes Mellitus Type 1NeurologyFemaleNeurology (clinical)ComplicationbusinessPolyneuropathyActa neurologica Scandinavica
researchProduct

Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients w…

2015

Background The aim of the study was to better characterise the immunological origin and the behaviour of interleukin (IL)-23-responsive innate lymphoid cells (ILCs) in the gut, synovial fluid (SF) and bone marrow (BM) of patients with ankylosing spondylitis (AS).Methods ILC1, ILC2 and ILC3 cells were determined and characterised by confocal microscopy and flow cytometry in ileal and BM biopsies, in peripheral blood (PB) and SF mononuclear cells obtained from patients with AS and controls. Mucosal vascular addressin cell adhesion molecule 1 (MADCAM-1), IL-7, IL-15 and aggregates of lymphoid tissue inducer cells (LTi) were evaluated by immunohistochemistry. The in vitro ability of epithelial …

AdultMalePathologymedicine.medical_specialtyAdolescentImmunologyHigh endothelial venulesImmunoglobulinsPeripheral blood mononuclear cellGeneral Biochemistry Genetics and Molecular BiologyInterleukin 22Young AdultMucoproteinsAnkylosing Spondylitis; Cytokines; InflammationRheumatologyBone MarrowIleumSynovial FluidAddressinImmunology and AllergyMedicineSynovial fluidHumansSpondylitis AnkylosingLymphocytesIntestinal MucosaCytokineAgedInterleukin-15InflammationMicroscopy ConfocalAnkylosing SpondylitibiologyNatural Cytotoxicity Triggering Receptor 2business.industryInterleukin-7InterleukinsInnate lymphoid cellInterleukin-17Middle AgedSettore MED/16 - Reumatologiamedicine.anatomical_structureLymphatic systemCase-Control Studiesbiology.proteinFemaleBone marrowbusinessCell Adhesion Molecules
researchProduct

Do Immune Complexes Formed with Autoantibodies Have a Role in the Maintenance of Immune Homeostasis Through Interaction with FC Receptors

2000

Natural autoantibodies play an important regulatory role in the maintenance of immune homeostasis. They act as a first line of defense against environmental pathogens like toxins, bacteria and erythrocytes. In humans they are mainly produced by CD5+ B cells that are under the control of a regulatory T cell population. Fc-gamma receptors are involved in antigen recognition and signal transduction and tuning, and some of the members of the FcR family have structural similarity to MHC molecules; they may interact with multiple Ig ligands and with non-Ig ligands. We discuss the interactions between immune-complexes formed with natural autoantibodies and Fc-gamma receptors and suggest that such …

Innate immune systembiologyRegulatory T cellImmunologyModels ImmunologicalDown-Regulationchemical and pharmacologic phenomenaAntigen-Antibody ComplexReceptors FcImmune receptorCD5 AntigensMajor histocompatibility complexImmune complexmedicine.anatomical_structureImmune systemAntigenImmunologymedicinebiology.proteinHomeostasisLeukocyte Common AntigensImmunology and AllergyReceptorAutoantibodiesAutoimmunity
researchProduct